Krebs Biochemicals Industries Q4 FY26 Results: Loss Rs 2 Cr

Krebs Biochemicals Industries Q4 FY26 results were declared on May 21, 2026. The company reported net loss of Rs 2 crore for the quarter ended March 31, 2026, up 75.0% YoY compared to loss of Rs 8 crore in Q4 FY25. Revenue from operations stood at Rs 7 crore, up 16.0% YoY. Results are on a Standalone basis. Krebs Biochemicals Industries is a Biochemicals company listed on Indian stock exchanges.

Click Here – Get Free Investment Predictions

Krebs Biochemicals Industries Q4 FY26 Financial Highlights

Metric	Q4 FY26 (Rs Cr)	Q4 FY25 (Rs Cr)	YoY Change
Revenue	7	6	+16.0%
Gross Loss	Rs 2 crore	7	+71.0%
Net Loss	2	8	+75.0%
Basis	Standalone

Note: Krebs Biochemicals Industries Q4 FY26 results declared May 21, 2026. Verify from BSE/NSE audited filings before investment decisions.

Krebs Biochemicals Industries Q4 FY26 Performance Analysis

The Krebs Biochemicals Industries Q4 FY26 results reflect the company’s operational performance in the January to March 2026 quarter. The quarter reflects near-term profitability challenges. Krebs Biochemicals Industries operates in the Biochemicals sector, which benefited from India’s GDP growth above 6.5% in FY26.

Revenue grew 16% YoY to Rs 7 crore, driven by strong demand and business expansion.

Screen the best stocks on the Univest Screener.

Key Factors Driving Krebs Biochemicals Industries Q4 FY26 Results

Revenue and Business Performance

Krebs Biochemicals Industries Q4 FY26 revenue of Rs 7 crore was up 16.0% YoY. Revenue momentum reflects steady demand in the Biochemicals business.

Profitability and Margins

the business net loss of Rs 2 crore up 75.0% YoY. Margin recovery and revenue growth will be the key operational levers entering FY27.

India Macro Backdrop

The January to March 2026 quarter benefited from India’s GDP growth above 6.5%, government capital expenditure of Rs 11.21 lakh crore for FY27, and resilient domestic consumption. RBI’s accommodative stance supported credit and demand conditions. The Biochemicals sector saw strong tailwinds during this period.

FY27 Outlook

Following the firm results, management commentary on FY27 revenue guidance, margin expansion roadmap, and capital allocation will be key investor watchpoints. The Biochemicals sector continues to benefit from India’s long-term structural growth.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.

Frequently Asked Questions on the company

Investments in securities are subject to market risk. This content is for educational purposes only. Verify all figures from BSE/NSE filings. Consult a SEBI-registered financial advisor.